US EditionNuevocor Strengthens Board with Appointment of Thierry Abribat
- Dr. Thierry Abribat has been appointed to the board of Nuevocor, bringing expertise from his successful biotech ventures, including the $1 billion acquisition of Amolyt Pharma by AstraZeneca.
- Nuevocor focuses on developing therapies for genetic cardiomyopathies using mechanobiology.
- Dr. Abribat expressed excitement about joining Nuevocor at a crucial time as it transitions to a clinical-stage company.
- Nuevocor is expanding its operations to Europe while being headquartered in Singapore and maintaining a U.S. office.
29 Articles
29 Articles
iRhythm Technologies Announces Board Member Retirements and New Director Appointments - Absci (NASDAQ:ABSI), Alphatec Holdings (NASDAQ:ATEC)
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rub…
journalgazette.net
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board of Directors.
Nuevocor Strengthens Board with Appointment of Thierry Abribat - PressReach
SINGAPORE, July 7, 2025 /PRNewswire/ — Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board of Directors. Dr. Thierry Abribat is a seasoned biotech executive and serial entrepreneur with a proven track record of founding, leading, and successfully exiting three biotechnology companies, each focused on…
Coverage Details
Bias Distribution
- 47% of the sources are Center
To view factuality data please Upgrade to Premium
